Hepion Pharmaceuticals Inc (HEPA)

[Raphael90]

Go To The Site, thelifesciencesreport And Read The Article

This is the beginning of the article:

"ContraVir Pharmaceuticals Inc. is interesting in that it is oriented differently than it was a year ago. The new CEO, James Sapirstein, has a great background with Gilead Sciences and Serono Laboratories Inc. His executive team also has experience commercializing the type of compounds ContraVir is developing. This company has two drugs to watch. Its lead drug, FV-100, is an oral nucleoside analog that helps treat pain associated with shingles. As an optimized prodrug, it is more readily absorbed. It is beginning Phase 3 trials this year. FV-100 will be ContraVir's first drug. This drug is interesting from both business and clinical science perspectives. It has the potential for an accelerated commercialization pathway and is likely to be approved, thus increasing cash flow while ContraVir develops the next item in its pipeline. ..

This is BEFORE the recent news on October 5th, this article is from September 9th.